Weight Loss & MetabolicStrong Evidence

Survodutide Peptide Therapy

Benefits, Side Effects, Cost & Protocols

Survodutide peptide molecular structure diagram from PubChem

Survodutide is an experimental dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim as a weight loss drug. Unlike other dual agonists, it is a glucagon analog rather than an oxyntomodulin analog.

ByChris Riley(CFA)&Alex Evans, PharmD, MBA(PharmD, MBA)|Updated May 19, 2026

Clinically Reviewed

Reviewed by Alex Evans, PharmD, MBA · Updated May 2026

Evidence-Based

Sourced from FDA, PubMed & ClinicalTrials.gov · View sources

FDA Status

Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.

Evidence

Strong Evidence

How Survodutide Works

Dual agonist that combines GLP-1 appetite suppression with glucagon's fat-burning and hepatic effects.

Survodutide FAQ

What is SURVODUTIDE?

Survodutide is a dual GLP-1 and glucagon receptor agonist being researched as a next-generation weight loss peptide with potential liver health benefits.

How does SURVODUTIDE work?

Dual agonist that combines GLP-1 appetite suppression with glucagon's fat-burning and hepatic effects.

Is SURVODUTIDE legal to buy?

SURVODUTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy SURVODUTIDE?

SURVODUTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does SURVODUTIDE belong to?

SURVODUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of SURVODUTIDE?

SURVODUTIDE has been studied for: Weight loss research, Dual mechanism, Liver health potential. GLP-1/glucagon dual agonist; emerging weight loss research.

Key Studies

61 total on PubMed0

Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial

Kosiborod MN, Platz E, Wharton S et al

JACC Heart FailPhase 3

Survodutide cardiovascular safety and efficacy in obesity with increased cardiovascular risk under investigation

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2)

Wharton S, le Roux CW, Kosiborod MN et al

Obesity (Silver Spring)Phase 3

Survodutide reduced body weight and achieved ≥5% weight loss in obesity with/without type 2 diabetes.

Survodutide reduced body weight and achieved ≥5% weight loss in obesity with/without type 2 diabetes

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)

le Roux CW, Wharton S, Bozkurt B et al

Diabetes Obes Metab · Diabetes Obes MetabPhase 3

Phase 3 trial investigating survodutide for weight loss in obesity without type 2 diabetes.

Phase 3 trial investigating survodutide for weight loss in obesity without type 2 diabetes

Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Survodutide Compound Data

Molecular Formula

C192H289N47O61

Molecular Weight

4232 g/mol

IUPAC Name

18-[[(1S)-4-[[2-[[(1S)-2-[[2-[[(1S)-2-[[2-[[2-[[(5S)-5-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[1-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]cyclobutanecarbonyl]amino]-5-oxo-pentanoyl]amino]acetyl]amino]-3-hydroxy-butanoyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-butanoyl]amino]-3-hydroxy-propanoyl]amino]-3-carboxy-propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxy-propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methyl-pentanoyl]amino]-3-carboxy-propanoyl]amino]-4-carboxy-butanoyl]amino]-5-guanidino-pentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-carboxy-propanoyl]amino]-3-phenyl-propanoyl]amino]-3-methyl-pentanoyl]amino]-6-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-amino-1-methyl-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-3-methyl-butyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxo-ethyl]amino]-6-oxo-hexyl]amino]-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]-1-carboxy-4-oxo-butyl]amino]-18-oxo-octadecanoic acid

View full compound on PubChem

Survodutide News

14 New Weight Loss Drugs - GoodRx

GoodRx · 2 days ago

ECO 2026: survodutide delivers renal and metabolic benefits in DKD model - Clinical Trials Arena

Clinical Trials Arena · 4 days ago

Addressing the bigger picture in obesity and metabolic dysfunction-associated steatohepatitis - Boehringer Ingelheim

Boehringer Ingelheim · 1 month ago

Dual-Agonist Survodutide Shows Significant Weight Loss in Phase III Obesity Trial - BioPharm International

BioPharm International · 20 days ago

‘Next-Gen’ GLP-1 Leads to 16% More Weight Loss. Is It Better Than Zepbound? - Healthline

Healthline · 14 days ago

News aggregated via Google News. Inclusion does not imply endorsement.

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptide therapies have not been evaluated by the FDA for most listed indications.All prices shown are estimates based on publicly available data and may not reflect current pricing — providers and brands set their own prices and can change them at any time. Always verify pricing directly with the provider before purchasing. Consult a licensed healthcare provider before starting any peptide protocol.

Ready to explore Survodutide with a provider?

Take our 2-minute quiz to get matched with a board-certified provider specializing in Survodutide.

Take the Quiz →